Tagged with R&D

orphan drugs Gabriela Pittis discusses the Argentinian healthcare system’s ability to diagnose, treat, and regulate rare diseases, and the country’s progress in further developing what is already the region’s most comprehensive system in this regard.   Is the Argentinian system able to reliably diagnose and treat rare diseases? “Rare diseases” is a…

clinical trials The Mexico country manager of the Swiss biopharmaceutical company discusses the recent restructuring process the subsidiary has been going through, the strategic importance of Mexico as a logistic and clinical research hub for the region as well as how the company is going digital.     In the past ten…

Sanofi Sanofi’s general manager for Malaysia, Singpoare and Brunei discusses the benefits of implementing of a new channel business model and proudly showcases the dengue vaccine, 20 years after the company initiated its research.   In 2010, Sanofi was undergoing a transformation to become a more diversified healthcare player. Could you tell…

basic research Manuel Díaz-Rubio, honorary president of Spain’s Royal Academy of Medicine, traces the history of Spain’s medical community over the last few decades, and emphasizes the importance of the pharmaceutical industry to the careers of doctors and physicians across the world.   You were head of Hospital San Carlos’ gastroenterology unit…

innovation Joaquin Poch, president of the Royal Academy of Medicine of Spain, outlines the Academy’s history and current initiatives.   What are the objectives of the Royal Academy of Medicine and what are your own personal objectives as president? In order to answer this question we have to go back to…

basic research The executive coordinator of GACTEC maps the current level of science and technology in Argentina and outlines the country’s ambitions in this area, which is to have an impact on innovation at the international level.     When was the cabinet was founded and what exactly is its role? The Scientific Technological Cabinet…

R&D Graham Skarnvad arrived to Spain as country manager of ALK’s Spanish affiliate at the end of 2009, right when the crisis was in full swing. Later on he took the full legal responsibility – also as: General Manager for Spain, and Portugal. He discusses his mandate and increased in investment…

commercialization The President of Argenomics highlights the position of his company as the bridge between science and business in Argentina.   Could you please provide an historical overview of Argenomics? Several years ago, during my time as an employee of a multinational pharma company, I met a medical doctor and a…

R&D The general manager of Ferring Argentina believes that the country has one of the strongest social security systems in Latin America, with high reimbursement levels and coverage for most chronic and serious diseases, providing pharmaceutical companies a receptive environment for specialized medicines.     Could you please give us a…

R&D Aplicaps was founded in 2008 with solely Spanish investments, when Spain was already suffering from a recession due to the real estate bubble. The company’s CEO, José Luis Martín Guinea, discusses the origins of the company in Portugal and the competitive services that Aplicaps offers to the Spanish pharmaceutical market.…

diagnostics Life Length was founded through the CNIO (Spanish National Cancer Research Center) combined with the support of the Botín Foundation, Matlin Associates and Dr. Maria Blasco’s work in telomeres. Stephen J. Matlin, CEO of Life Length, discusses the potential of the company’s diagnostic test to become a standard biomarker for…

R&D When Jordi Martí came to Celgene in December 2012, one of his main goals was to create a change in the affiliate’s model. The VP Managing Director of Celgene Spain & Portugal explains the new methods implemented in the affiliate, and the importance of the company’s research center in Seville,…